Metabolic Retroversion of Piperaquine (PQ) via Hepatic Cytochrome P450–Mediated <i>N</i>-Oxidation and Reduction: Not an Important Contributor to the Prolonged Elimination of PQ

Xie, Yuewu; Zhang, Yunrui; Liu, Huixiang; Xing, Jie

doi:10.1124/dmd.120.000306

Cited by 5 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3), had been extensively used as a monotherapy but it is now commonly used as a partner drug with dihydroartemisinin in the ACT. Piperaquine is metabolized primarily by CYP3A4 and CYP3A5 into two major metabolites, piperaquine N-oxide and piperaquine N, N-dioxide, and both metabolites are biologically active contributing to the e cacy of piperaquine [47]. The variants of CYP3A4 and CYP3A5 genes and their occurrence frequencies are shown in Table 1.…”

Section: Piperaquinementioning

confidence: 99%

Insights and Current Perspectives on Pharmacogenomics of Antimalarial Drugs

Soyinka

Nnadi

Onyeji

2022

Preprint

View full text Add to dashboard Cite

Malaria constitutes a major public health concern in tropical and other malaria-endemic regions. Genetic and non-genetic factors are known to influence the pharmacokinetics and/or pharmacodynamics of drugs including antimalarial drugs resulting in variability in drug responses. This article aimed to update perspectives on pharmacogenomics and also provide an updated appraisal of genetic variability in drug-metabolizing enzymes which alter the disposition of antimalarial drugs causing variations in treatment outcomes. Important literature databases such as Elsevier, IEEExplore, Pubmed, Scopus, Web of Science, Google Scholar, ProQuest, ScienceDirect, and BioMed Central were selected based on the quality, extant content, and broad area of the discipline. The specific keywords related to the study were identified and used for the study purposedly to identify related works. Advances in genetic research have facilitated the identification of Single Nucleotide Polymorphisms (SNPs) that alter the activity of drug-metabolizing enzymes that metabolize most antimalarial drugs. There is an association between isoforms of CYP450 gene variants and the efficacy of some antimalarial drugs, and this can be applied to the optimization of malarial therapy. Although identification of cytochrome P450 (CYP450) gene variants can be used for personalization of malaria treatment, several challenges are encountered in this process but some resources provide education and guidelines on how to use the pharmacogenetic results of specific drugs.

show abstract

Section: Piperaquinementioning

confidence: 99%